Visa inched up in after-hours trading, as it reported quarterly numbers that outpaced expectations. The solid, but unspectacular, outperformance — it beat earnings-per-share estimates by a penny — is par for the course for a company that’s developed a reputation as a boring, but consistent, moneymaker seemingly indifferent to economic conditions.
Makers of the affordable data storage technology known as hard disk drives have become hot stocks amid the AI boom.
The market seems to like the better-than-expected news.
Shares of Lucid vaulted briefly on Tuesday afternoon following the company’s announcement that it will team up with Nvidia to bring Level 4 autonomous driving to its future vehicles.
A still unnamed midsized SUV by Lucid, planned for 2026, will feature lidar and radar provided by Nvidia’s ecosystem. Ultimately, the automaker said it aims to create the “first true eyes-off, hands-off, and mind-off (L4) consumer owned autonomous vehicle.” Level 4 autonomous vehicles, like Waymo’s robotaxis, operate without human intervention.
The Nvidia partnership will also bring new automated features to Lucid’s Gravity SUV, the luxury EV maker said. Its shares rose more than 6% before losing all those gains and dipping into the red.
Lucid and Nvidia’s announcements came along with a host of other new partnerships at the chip designer’s GPU Technology Conference in Washington, DC.
Eli Lilly is partnering with Nvidia to build “the most powerful supercomputer owned and operated by a pharmaceutical company” to help discover new medicines.
The drugmaker announced the deal on Tuesday, following a slew of deals Nvidia announced with other companies. Lilly did not specify the terms of the deal but did say it is using 1,000 Nvidia GPUs.
Lilly — the maker of the blockbuster diabetes and weight-loss shots Mounjaro and Zepbound — said the supercomputer “will help scientists identify, optimize and validate new molecules.”
“With purpose-built AI models and AI, we can set a new scientific standard that accelerates innovation to deliver medicines to more patients, faster,” Diogo Rau, Lilly’s chief information and digital officer, said in a statement.
